M J Feito1, M Vila2, M C Matesanz3, J Linares4, G Gonçalves5, P A A P Marques6, M Vallet-Regí7, J M Rojo8, M T Portolés9. 1. Department of Biochemistry and Molecular Biology I, Faculty of Chemistry, Universidad Complutense, 28040 Madrid, Spain. Electronic address: mjfeito@pdi.ucm.es. 2. Department of Inorganic and Bioinorganic Chemistry, Faculty of Pharmacy, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, 28040 Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Spain; TEMA-NRD, Mechanical Engineering Department and Aveiro Institute of Nanotechnology (AIN), University of Aveiro, 3810-193 Aveiro, Portugal. Electronic address: mvila@farm.ucm.es. 3. Department of Biochemistry and Molecular Biology I, Faculty of Chemistry, Universidad Complutense, 28040 Madrid, Spain. Electronic address: conchitamatesanz@hotmail.com. 4. Department of Biochemistry and Molecular Biology I, Faculty of Chemistry, Universidad Complutense, 28040 Madrid, Spain. Electronic address: javilinares_88@hotmail.com. 5. TEMA-NRD, Mechanical Engineering Department and Aveiro Institute of Nanotechnology (AIN), University of Aveiro, 3810-193 Aveiro, Portugal. Electronic address: ggoncalves@ua.pt. 6. TEMA-NRD, Mechanical Engineering Department and Aveiro Institute of Nanotechnology (AIN), University of Aveiro, 3810-193 Aveiro, Portugal. Electronic address: paulam@ua.pt. 7. Department of Inorganic and Bioinorganic Chemistry, Faculty of Pharmacy, UCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, 28040 Madrid, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Spain. Electronic address: vallet@farm.ucm.es. 8. Department of Cellular and Molecular Medicine, Centro de Investigaciones Biológicas, CSIC, 28040 Madrid, Spain. Electronic address: jmrojo@cib.csic.es. 9. Department of Biochemistry and Molecular Biology I, Faculty of Chemistry, Universidad Complutense, 28040 Madrid, Spain. Electronic address: portoles@quim.ucm.es.
Abstract
HYPOTHESIS: Graphene oxide (GO) has attracted the scientific community attention due to its novel properties and wide range of potential applications including hyperthermia cancer therapy. However, little is known about the GO effects on the immune function which involves both innate and adaptive defence mechanisms through the activation of different cell populations and secretion of several cytokines. The effect of different GO nanosheets designed for hyperthermia cancer therapy on macrophage and lymphocyte function should be determined before using GO for this application. EXPERIMENTS: The effects of GO nanosheets with 1 (1-GOs) and 6 arms (6-GOs) of polyethylene glycol on RAW-264.7 macrophages and primary splenocytes (as approximation to the in vivo situation) were evaluated through the proinflammatory cytokine secretion and the modulation of cell proliferation in the presence of specific stimuli for either T-lymphocytes (concanavalin A, anti-CD3 antibody) or B-lymphocytes/macrophages (lipopolysaccharide). FINDINGS: 6-GOs significantly increased the secretion of TNF-α by RAW-264.7 macrophages without alteration of IL-6 and IL-1β levels. The treatment of primary splenocytes with 1-GOs and 6-GOs in the presence of concanavalin A, anti-CD3 antibody and lipopolysaccharide, produced significant dose-dependent decreases of cell proliferation and IL-6 levels, revealing weak inflammatory properties of GOs which are favourable for hyperthermia cancer therapy.
HYPOTHESIS: Graphene oxide (GO) has attracted the scientific community attention due to its novel properties and wide range of potential applications including hyperthermia cancer therapy. However, little is known about the GO effects on the immune function which involves both innate and adaptive defence mechanisms through the activation of different cell populations and secretion of several cytokines. The effect of different GO nanosheets designed for hyperthermia cancer therapy on macrophage and lymphocyte function should be determined before using GO for this application. EXPERIMENTS: The effects of GO nanosheets with 1 (1-GOs) and 6 arms (6-GOs) of polyethylene glycol on RAW-264.7 macrophages and primary splenocytes (as approximation to the in vivo situation) were evaluated through the proinflammatory cytokine secretion and the modulation of cell proliferation in the presence of specific stimuli for either T-lymphocytes (concanavalin A, anti-CD3 antibody) or B-lymphocytes/macrophages (lipopolysaccharide). FINDINGS:6-GOs significantly increased the secretion of TNF-α by RAW-264.7 macrophages without alteration of IL-6 and IL-1β levels. The treatment of primary splenocytes with 1-GOs and 6-GOs in the presence of concanavalin A, anti-CD3 antibody and lipopolysaccharide, produced significant dose-dependent decreases of cell proliferation and IL-6 levels, revealing weak inflammatory properties of GOs which are favourable for hyperthermia cancer therapy.
Authors: Fatemeh Sharifi; Su Su Htwe; Martina Righi; Hua Liu; Anna Pietralunga; Ozlem Yesil-Celiktas; Sushila Maharjan; Byung-Hyun Cha; Su Ryon Shin; Mehmet Remzi Dokmeci; Nihal Engin Vrana; Amir M Ghaemmaghami; Ali Khademhosseini; Yu Shrike Zhang Journal: Adv Healthc Mater Date: 2019-01-29 Impact factor: 9.933
Authors: Kim Lategan; Hend Alghadi; Mohamed Bayati; Maria Fidalgo de Cortalezzi; Edmund Pool Journal: Nanomaterials (Basel) Date: 2018-02-24 Impact factor: 5.076
Authors: Dominika Stygar; Aleksandra Pogorzelska; Elżbieta Chełmecka; Bronisława Skrzep-Poloczek; Barbara Bażanów; Tomasz Gębarowski; Jerzy Jochem; Jiří Henych Journal: Antioxidants (Basel) Date: 2021-05-11
Authors: Gabriela H Da Silva; Lidiane S Franqui; Romana Petry; Marcella T Maia; Leandro C Fonseca; Adalberto Fazzio; Oswaldo L Alves; Diego Stéfani T Martinez Journal: Front Immunol Date: 2021-06-03 Impact factor: 7.561